Analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a note issued to investors on Wednesday. The firm set a "hold" rating on the medical research company's stock.
Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th.
Read Our Latest Stock Report on Cytosorbents
Cytosorbents Price Performance
Shares of CTSO stock traded up $0.02 during trading on Wednesday, hitting $0.97. The company had a trading volume of 73,085 shares, compared to its average volume of 123,998. The stock's 50-day moving average price is $1.05 and its 200 day moving average price is $1.02. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The firm has a market capitalization of $52.77 million, a P/E ratio of -2.64 and a beta of 0.57.
Institutional Trading of Cytosorbents
Several institutional investors have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents during the 3rd quarter worth approximately $51,000. Geode Capital Management LLC boosted its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after buying an additional 32,415 shares in the last quarter. CM Management LLC boosted its holdings in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock worth $598,000 after buying an additional 25,000 shares in the last quarter. Finally, Sargent Investment Group LLC boosted its holdings in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock worth $1,008,000 after buying an additional 67,181 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors.
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Featured Articles
Before you consider Cytosorbents, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.
While Cytosorbents currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
